The ICIs series cover 1267 genes. Using next-generation sequencing (NGS) technology of target gene capture, it comprehensively and accurately detects target gene capture exons and single nucleotide variations (SNV), short fragment insertion or deletion variations (InDel), gene copy number variations (CNV) and gene rearrangement/fusion within the intron range of standard spliceosomes. It also evaluates immune indicators such as TMB, TNB, MSI, and HLA LOH. Using immunohistochemistry (IHC) technology, it detects the representative indicators of tumor immune-microenvironment such as PD-L1 and CD8+TIL, to provide reference and guidance for immunotherapy of solid tumor patients.
▪ Has the only neoantigen algorithm validated by the Tumor Neoantigen Selection Alliance (TESLA) in China
▪ The blood edition/body fluid edition bTMB uses a machine learning model, which is highly consistent with the tissue TMB (0.90)
▪ The mutation information is accurately described according to the HGVS standard terms. The germline genetic mutations are classified according to the ACMG guidelines for the classification of the pathogenicity of mutations, and the clinical medication is suggested based on clinical based medical evidence
▪ Ultra-high depth sequencing and the limit of detection of ctDNA is 0.1%
Copyright©2021
Shenzhen yucebio Technology Co., Ltd. all rights reserved
Yueicp no.16128839
